Director at Kestra Medical (KMTS) sells 15,000 common shares

Rhea-AI Filing Summary

Kestra Medical Technologies director and officer Brian Daniel Webster reported selling a total of 15,000 Common Shares in open-market transactions. The sales occurred on May 15, 2026 at weighted average prices of $21.4635 and $20.5287 per share. The filing states these transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025, indicating they were scheduled in advance rather than timed discretionarily.

Insider Trade Summary 10b5-1

Net Seller: 15,000 shares ($314,329)

Net Sell 2 txns

Insider Webster Brian Daniel

Role See Remarks

Sold 15,000 shs ($314K)

Type	Security	Shares	Price	Value
Sale	Common Shares	8,155	$20.5287	$167K
Sale	Common Shares	6,845	$21.4635	$147K

Holdings After Transaction: Common Shares — 341,631 shares (Direct, null)

Footnotes (1)

1. The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $20.2200 to $20.2115. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $21.2433 to $21.6300. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

Key Figures

Total shares sold: 15,000 shares First sale block: 6,845 shares at $21.4635/share Second sale block: 8,155 shares at $20.5287/share +1 more

4 metrics

Total shares sold 15,000 shares Common Shares sold on May 15, 2026

First sale block 6,845 shares at $21.4635/share Open-market sale of Common Shares

Second sale block 8,155 shares at $20.5287/share Open-market sale of Common Shares

Trading plan adoption date September 29, 2025 Rule 10b5-1 plan governing reported sales

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale

3 terms

Rule 10b5-1 trading plan regulatory

"The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Webster Brian Daniel

(Last) (First) (Middle)

3933 LAKE WASHINGTON BLVD NE, SUITE 200

(Street)

KIRKLAND WASHINGTON 98033

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	05/15/2026	05/15/2026	S(1)		8,155	D	$20.5287(2)	341,631	D
Common Shares	05/15/2026	05/15/2026	S(1)		6,845	D	$21.4635(3)	334,786	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.

2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $20.2200 to $20.2115. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

3. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $21.2433 to $21.6300. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

Remarks:

President and Chief Executive Officer

	/s/ Brian Daniel Webster	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did KMTS director Brian Daniel Webster report?

Brian Daniel Webster reported selling 15,000 Kestra Medical Technologies Common Shares. The Form 4 shows two open-market sale transactions on May 15, 2026, totaling 15,000 shares, reflecting a modest reduction in his direct holdings while retaining a large remaining position.

At what prices did Brian Daniel Webster sell KMTS shares?

Webster’s KMTS share sales were executed at weighted average prices around $21.46 and $20.53. One block of 6,845 shares priced at $21.4635 and another 8,155 shares at $20.5287, with detailed price ranges provided through weighted-average footnotes.

Were Brian Daniel Webster’s KMTS share sales pre-planned?

Yes, the sales were made under a Rule 10b5-1 trading plan. A footnote explains the transactions occurred pursuant to a trading plan adopted on September 29, 2025, indicating they were scheduled in advance rather than opportunistic discretionary trades.

How many KMTS shares did Brian Daniel Webster sell in total on May 15, 2026?

He sold a total of 15,000 Kestra Medical Technologies Common Shares. The Form 4 transaction summary combines two open-market sale entries—6,845 shares and 8,155 shares—into a net-sell position of 15,000 shares for that date.

Does the Form 4 show any option exercises or derivative transactions for KMTS?

No derivative exercises or option transactions are reported in this Form 4. The derivative summary is empty, and the transaction summary lists zero exercise transactions, indicating only common share sales were reported for this filing date.